2-氯-5-甲基烟酸 | 66909-30-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-5-甲基烟酸
• 中文别名: 2-氯-5-甲基吡啶-3-甲酸；2-氯-5-甲基吡啶-3-羧酸
• 英文名称: 2-chloro-5-methylnicotinic acid
• 英文别名: 2-chloro-5-methyl-3-pyridinecarboxylic acid；2-chloro-5-methylpyridine-3-carboxylic acid
• CAS: 66909-30-6
• 化学式: C₇H₆ClNO₂
• mdl: MFCD07375371
• 分子量: 171.583
• InChiKey: HGTOSTXLRLIKCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  199 °C
• 沸点：
  331.2±37.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P261,P305+P351+P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-5-methylnicotinic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-5-methylnicotinic acid
CAS number: 66909-30-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6ClNO2
Molecular weight: 171.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-5-甲基烟酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-chloro-5-methylnicotinoylchloride
  参考文献：
  名称：

  [EN] Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
  [FR] NOUVEAU DÉRIVÉ D'AZÉPINE 5,6-DIHYDRO-4 H-BENZO[B]THIÉNO-[2,3-D]

  摘要：

  提供了一种5,6-二氢-4H-苯并[b]噻吩-[2,3-d]氮杂环庚烷衍生物，可用于治疗呼吸道合胞病毒（RSV）感染以及预防与RSV感染相关的疾病。（化学式（I））

  公开号：

  WO2016055791A1
• 作为产物：
  描述：

  二氧化碳 在 2,2,6,6-四甲基哌啶 、 正丁基锂 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.0h， 生成 2-氯-5-甲基烟酸
  参考文献：
  名称：

  Compounds

  摘要：

  这项发明涉及一般式(I)的烟酰胺衍生物： 其中R1、Z和R2具有本文所定义的含义，并涉及用于制备、用于制备的中间体、含有和使用这种衍生物的组合物的过程。

  公开号：

  US20050020611A1

文献信息

• [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE UTILES EN TANT QU'INHIBITEURS DE PDE4
  申请人：PFIZER LTD

  公开号：WO2005009965A1

  公开（公告）日：2005-02-03

  This invention relates to nicotinamide derivative of general formula (I), in which R1, R2 and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.

  这项发明涉及一般式(I)的烟酰胺衍生物，其中R1、R2和R3具有本文中定义的含义，以及含有这些衍生物并将其用作PDE4抑制剂的组合物。
• [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY<br/>[FR] INHIBITEURS DE TRYPTOPHANE DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2016024233A1

  公开（公告）日：2016-02-18

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有IDO1和/or TDO抑制活性的3-氨基异恶唑啉化合物I的药物组合物，其中W是CR1，N或N-氧化物；X是CR2，N或N-氧化物；Y是CR3，N或N-氧化物；Z是CR4，N或N-氧化物；W、X、Y和Z中的至少一个是N或N-氧化物；R9和R10如所定义。还描述了使用这些化合物治疗各种疾病，如癌症的方法。
• Compounds
  申请人：Barber Gordon Christopher

  公开号：US20050020611A1

  公开（公告）日：2005-01-27

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  这项发明涉及一般式(I)的烟酰胺衍生物： 其中R1、Z和R2具有本文所定义的含义，并涉及用于制备、用于制备的中间体、含有和使用这种衍生物的组合物的过程。
• [EN] SPIRO-OXAZOLONES<br/>[FR] SPIRO-OXAZOLONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015091411A1

  公开（公告）日：2015-06-25

  The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

  本发明提供了螺环噁唑酮，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本化合物在外周和中枢作用下，对于不当分泌加压素、焦虑、抑郁症、强迫症、自闭症谱系障碍、精神分裂症、攻击性行为和相位转移性睡眠障碍，特别是时差反应等症状的治疗具有用处。
• 4H-吡啶并[3,2-e][1,3]噻嗪-4-酮类衍生物 及其应用
  申请人：沈阳药科大学

  公开号：CN104672256B

  公开（公告）日：2017-10-31

  本发明涉及医药技术领域，公开了一种新颖的4H‑吡啶并[3,2‑e][1,3]噻嗪‑4‑酮类衍生物及其制备方法，设计并合成了一系列结构新颖的4H‑吡啶并[3,2‑e][1,3]噻嗪‑4‑酮类系列物（I）及一种以该类化合物或其在药学上可接受的溶剂化物、光学异构体或多晶型物为活性成分的药物。并采用二倍浓度稀释法对其体外抗真菌活性进行了测试，旨在建立初步的构效关系，从中发现活性高、毒性小、可供临床前研究的新型抗真菌化合物作为抗真菌剂，本发明的化合物对临床上常见的致病真菌有较强的杀灭作用，并有望克服目前临床上广泛使用的唑类抗真菌药的毒副作用大、易产生耐药性等缺陷。